Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
32
datasets available to search
ShareScore release 0.9.0
Dataset results
32 results for “ampicillin”
Adaptation of Thioalkalivibrio thiocyanoxidans to ampicillin and streptomycin
<p>Bacteria of the genus Thioalkalivibrio can be found in soda lakes. These lakes are naturally alkaline and hypersaline environments, with a pH ranging from 9.5 to 10.5. In soda lakes are a lot of different stress factors, like arsenic and uranium. Thioalkalivibrio needs to adapt continuously to changing conditions and to resistant to metals and unknown antibiotics. In this study, the bacteria of Thioalkalivibrio was adapted to 2 different kinds of antibiotics, ampicillin and streptomycin. The bacteria adapted from 0.1 µg/mL to 0.8 µg/mL of ampicillin and from 1.0 µg/mL to 8.0 µg/mL of streptomycin. The bacteria are most likely not adapted to ampicillin because of fast degradation in the medium was found. Also during growth with sodium, there was no difference between adapted and non-adapted cultures. However, it is likely that the bacteria did adapted to streptomycin. The bacteria showed difference in growth when sodium was present between the adapted and non-adapted cultures. Changes in the Rep-pcr profiles for all cultures which grew with ampicillin were detected. No changes were found in the rep-PCR profiles for all cultures which grew with streptomycin. Higher relative expression of arcB was found in cultures that were adapted to ampicillin. For further research, transcriptomics could be used to obtain a complete picture of the gene expression changes.</p>
Figure 6: Theoretical Prediction of Ampicillin Resistance in Enterococcus faecium (2020-2030)
<p><strong>Figure 6: Theoretical Prediction of Ampicillin Resistance in Enterococcus faecium (2020-2030)</strong></p> <p> </p>
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
ClinicalTrials.gov study NCT00368537. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis
ClinicalTrials.gov study NCT00879190. IPD Sharing: NO. Countries: 1. Publications: 0.
Species interactions drive the spread of ampicillin resistance in human-associated gut microbiota
<p><span><span><span><span><span><span><span><span><span><span><span><b>Background and objectives</b></span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>Slowing the spread of antimicrobial resistance is urgent if we are to continue treating infectious diseases successfully. There is increasing evidence microbial interactions between and within species are significant drivers of resistance. On one hand, cross-protection by resistant genotypes can shelter susceptible microbes from the adverse effects of antibiotics, reducing the advantage of resistance. On the other hand, antibiotic-mediated killing of susceptible genotypes can alleviate competition and allow resistant strains to thrive (competitive release). Here, by observing interactions both within and between species in microbial communities sampled from humans, we investigate the potential role for cross-protection and competitive release in driving the spread of ampicillin resistance in the ubiquitous gut commensal and opportunistic pathogen <i>Escherichia coli</i>. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methodology</b></span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>Using anaerobic gut microcosms comprising <i>E. coli</i> embedded within gut microbiota sampled from humans, we tested for cross-protection and competitive release both within and between species in response to the clinically important beta-lactam antibiotic ampicillin. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results</b></span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>While cross-protection gave an advantage to antibiotic-susceptible <i>E. coli</i> in standard laboratory conditions (well-mixed LB medium), competitive release instead drove the spread of antibiotic-resistant <i>E. coli</i> in gut microcosms (ampicillin boosted growth of resistant bacteria in the presence of susceptible strains). </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusions and implications</b></span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>Competition between resistant strains and other members of the gut microbiota can restrict the spread of ampicillin resistance. If antibiotic therapy alleviates competition with resident microbes by killing susceptible strains, as here, microbiota-based interventions that restore competition could be key for slowing the spread of resistance. </span></span></span></span></span></span></span></span></span></span></span></p>
T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam
ClinicalTrials.gov study NCT00630513. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis
ClinicalTrials.gov study NCT07113587. IPD Sharing: YES. Countries: 1. Publications: 6.
RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia
ClinicalTrials.gov study NCT03369093. IPD Sharing: NO. Countries: 1. Publications: 1.
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
ClinicalTrials.gov study NCT05922124. IPD Sharing: YES. Countries: 1. Publications: 2.
Species interactions drive the spread of ampicillin resistance in human-associated gut microbiota
Open the record for dataset details and reuse information.
Acinetobacter oleivorans DR1 : Cell treated Ampicillin 100 µg/ml in nutrient media
GEO Series GSE58166. Acinetobacter oleivorans DR1. 1 samples. Type: Expression profiling by high throughput sequencing.
Analysis of differential gene expression in the Streptococcus sanguinis SK36 treated with sub-inhibitory dose of Ampicillin for 3 time periods.
GEO Series GSE97218. Streptococcus sanguinis. 12 samples. Type: Expression profiling by high throughput sequencing.
Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model
GEO Series GSE159901. Streptococcus pneumoniae. 3 samples. Type: Expression profiling by high throughput sequencing.
Ampicillin treatment casues dysbiosis that affects transcriptome in spleen and mesenteric lymph nodes [nCounter Mouse Immunology Panel]
GEO Series GSE138331. Mus musculus. 12 samples. Type: Expression profiling by array.
Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy
ClinicalTrials.gov study NCT03129620. IPD Sharing: NO. Countries: 1. Publications: 0.
Ampicillin-sulbactam Resistant E.Coli at UPMC
ClinicalTrials.gov study NCT00619580. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients
ClinicalTrials.gov study NCT02007603. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ampicillin for DYT-1 Dystonia Motor Symptoms
ClinicalTrials.gov study NCT01433757. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Azithromycin and Ampicillin for Late PPROM
ClinicalTrials.gov study NCT07183462. IPD Sharing: NO. Countries: 1. Publications: 0.
Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients
ClinicalTrials.gov study NCT02427932. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.